Those that are saying this is basal(long acting insulin) are thinking about this in the wrong way. Right on the webpage www.go-vgo.com/ "A separate prescription for a U100 fast-acting insulin is required to fill V-Go." So that means it is filled with "fast-acting" insulin. Hence it is using meal time insulin to keep background insulin levels up. I believe Afrezza can be made into a suspension to use in pumps.....anyone remember the "Juvenile Diabetes Research Foundation for Artificial Pancreas Project" it used Afrezza. investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-providing-afrezzar-juvenile-diabetes
Last Edit: May 17, 2022 9:14:35 GMT -5 by anderson
All you liquid monomer people out there..... If rapid acting insulin could be made into a monomer and injected subq, I think Lilly, Sanofi and Nova Nordisk would be working on it, have it, etc etc.
Years ago, a brief post by a long gone poster, monomeric would become diameric and hexameric subq, under the skin. They are proteins with ion charges and attractions.
#Nasty Women. It's just such crazy business. They lie, we know they are lying, they know we know they are lying, and tomorrow is another day - of lies. person, woman, man, camera, TV. Twice impeached. Indicted 4 times.
Can they add a CGM feature to this device? It already has a needle in you, and smart software combined with CGM, background insulin and Afrezza bolus, could be the direction they want to go. If they intend to put Afrezza in liquid form, I’d say they’re giving up on inhaled insulin.
All you liquid monomer people out there..... If rapid acting insulin could be made into a monomer and injected subq, I think Lilly, Sanofi and Nova Nordisk would be working on it, have it, etc etc.
Years ago, a brief post by a long gone poster, monomeric would become diameric and hexameric subq, under the skin. They are proteins with ion charges and attractions.
If you think that Novo, Lilly & Snakeofi aren't doing research on liquid monomer insulin then you have your head in the ground...
It's all about stability and Al Mann has been the only person/company to stabilize it and deliver it commercially.
Read the article I posted...
“When I ran the blood tests and started plotting the data, I almost couldn’t believe how good it looked,” said Maikawa.
“It’s really unprecedented,” said Appel, who is senior author of the paper. “This has been a major target for many big pharmaceutical companies for decades.”
The monomeric insulin also finished its action sooner. Both beginning and ending activity sooner makes it easier for people to use insulin in coordination with mealtime glucose levels to appropriately manage their blood sugar levels.
goyocafe - If they do decide to convert Afrezza into liquid form, that doesn't mean they are giving up on the inhaled form. The inhaled form will always be faster than a liquid form but there are certain groups that can't inhale (smokers, etc.) and if one of the big 3 develop an equivalent monomeric insulin they have the ability to market that as we've already seen with other insulins they claim to be faster.
I don't even know if it's something the company is looking at but I don't think it's an unreasonable option to look at.
Here is a 5-7 minute read from a third-party verywellhealth.com (updated August 25, 2021) entitled "What to Know About V-Go for Treating Type 2 Diabetes; A disposable insulin pump that comes as a patch".
All you liquid monomer people out there..... If rapid acting insulin could be made into a monomer and injected subq, I think Lilly, Sanofi and Nova Nordisk would be working on it, have it, etc etc.
Years ago, a brief post by a long gone poster, monomeric would become diameric and hexameric subq, under the skin. They are proteins with ion charges and attractions.
If you think that Novo, Lilly & Snakeofi aren't doing research on liquid monomer insulin then you have your head in the ground...
It's all about stability and Al Mann has been the only person/company to stabilize it and deliver it commercially.
Read the article I posted...
“When I ran the blood tests and started plotting the data, I almost couldn’t believe how good it looked,” said Maikawa.
“It’s really unprecedented,” said Appel, who is senior author of the paper. “This has been a major target for many big pharmaceutical companies for decades.”
The monomeric insulin also finished its action sooner. Both beginning and ending activity sooner makes it easier for people to use insulin in coordination with mealtime glucose levels to appropriately manage their blood sugar levels.
Of course harryx1, I have no doubt there is work being done. Al Mann found the way to deliver monomeric insulin.
Remember Cathode, I miss Cathode, look at the date.
#Nasty Women. It's just such crazy business. They lie, we know they are lying, they know we know they are lying, and tomorrow is another day - of lies. person, woman, man, camera, TV. Twice impeached. Indicted 4 times.
peppy - Read the article, the reason liquid insulin is Hexamer, Dimer is because of stability issues of being in the liquid. Once the hexamer reaches the bloodstream it needs to be broken down to a monomer. They have never been able to deliver a monomer insulin in liquid because of stability. Yes it takes time for the liquid to move through all the layers to the bloodstream but then wouldn't need to be broken down once there, just like Afrezza works now, into the lungs, goes through a single layer of cell and into the bloodstream, ready to work.
peppy - Read the article, the reason liquid insulin is Hexamer, Dimer is because of stability issues of being in the liquid. Once the hexamer reaches the bloodstream it needs to be broken down to a monomer. They have never been able to deliver a monomer insulin in liquid because of stability. Yes it takes time for the liquid to move through all the layers to the bloodstream but then wouldn't need to be broken down once there, just like Afrezza works now, into the lungs, goes through a single layer of cell and into the bloodstream, ready to work.
In commercial insulin — which typically remains stable for about 10 hours in accelerated aging tests — the polymer drastically increased the duration of stability for upwards of a month. The next step was to see how the polymer affected monomeric insulin, which on its own aggregates in 1-2 hours. It was another welcome victory when the researchers confirmed that their formulation could remain stable for over 24 hours under stress.
“In terms of stability, we took a big step backward by making the insulin monomeric. Then, by adding our polymer, we met more than double the stability of the current commercial standard,” said Caitlin Maikawa, a graduate student in the Appel lab and co-lead author of the paper.
the researchers were able to evaluate their new monomeric insulin formulation in diabetic pigs — the most advanced non-human animal model — and found that their insulin reached 90 percent of its peak activity within five minutes after the insulin injection.For comparison, the commercial fast-acting insulin began showing significant activity only after 10 minutes.Furthermore, the monomeric insulin activity peaked at about 10 minutes while the commercial insulin required 25 minutes. In humans, this difference could translate to a four-fold decrease in the time insulin takes to reach peak activity.
HMMMMM.
For comparison RAA times, look at the terms, the words used carefully.
90 percent of its peak activity within five minutes after the insulin injection.
the commercial fast-acting insulin began showing significant activity only after 10 minutes. Furthermore, the monomeric insulin activity peaked at about 10 minutes while the commercial insulin required 25 minutes.
*My point, the times the study finding are giving are not adding up, as far as their comparators times.
#Nasty Women. It's just such crazy business. They lie, we know they are lying, they know we know they are lying, and tomorrow is another day - of lies. person, woman, man, camera, TV. Twice impeached. Indicted 4 times.
Post by pbaumgarten on May 17, 2022 11:29:29 GMT -5
How much does the device cost the consumer? I did a quick read of several different health insurer policies and they all classified the V-go as "investigational," which I presume is their way of saying they won't pay for it. I don't see the benefit of buying a device that doesn't have good insurance coverage.
Post by tarheelblue004 on May 17, 2022 11:52:06 GMT -5
It seems like a way for MannKind to offer a product that complements traditional RAA injected insulin while Afrezza still competes with RAA insulin. The salesforce would still position Afrezza as the optimal mealtime insulin due to inhalation, ultra rapid acting, etc. But for doctors and patients who still prefer RAA....we can now help with that too! It is not like MannKind purchased an RAA insulin that competes with Afrezza. The company purchased a delivery device that improves experience and outcomes for patients using RAA. MannKind now has an offer for doctors and patients that prefer RAA over Afrezza while they work on educating the same doctors and patients on the benefits of Afrezza to increase adoption.
Perhaps not the easiest balance to strike, but doesn't seem like the hardest either. It opens the addressable market of patients tremendously and helps the company stay in front of all doctors. MannKind can not let the new product / solution reduce the company's focus on Afrezza education, promotion and sales. If the company does not...it seems genius to me. Thoughts?
Last Edit: May 17, 2022 11:53:51 GMT -5 by tarheelblue004
